First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) 

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated.
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)  D.P. Modest, I. Ricard,
Volume 14, Issue 12, Pages (November 2013)
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front- line therapy with novel agents combinations  Aurelio Lopez, Maria-Victoria.
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase.
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)  Axel.
Bo Karlsson, Gunilla Burell, Ulla-Maria Anderberg, Kurt Svärdsudd 
Rare cancers of the head and neck area in Europe
European Journal of Cancer
Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1–3 brain metastases: Results.
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)  M. Yoshida, K. Muro, A. Tsuji,
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group  Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.
Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without.
Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma – Results and treatment recommendations.
Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review.
Volume 50, Issue 1, Pages (July 2006)
High smoking cessation rate in Crohn's disease patients after physician advice – The TABACROHN Study  Tiago Nunes, Maria Josefina Etchevers, Olga Merino,
Association between 11 genetic polymorphisms in folate-metabolising genes and head and neck cancer risk  Ana Lívia Silva Galbiatti, Lidia Maria Rebolho.
European Journal of Cancer
A. Gupta, K. Shridhar, P.K. Dhillon  European Journal of Cancer 
Volume 60, Issue 2, Pages (August 2011)
Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement  Jorge Cuenca, José A. García-Erce, Fernando.
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group  Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Volume 74, Issue 1, Pages (July 2018)
A technical improvement in retropharyngeal carotid reconstruction
Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making  Emilio Bertani, Massimo.
Immigration and viral hepatitis
Volume 67, Issue 3, Pages (March 2015)
Hepatic resection of non-colorectal and non-neuroendocrine liver metastases – Survival benefit for patients with non-gastrointestinal primary cancers.
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Efficacy of intralesional photodynamic therapy for the treatment of hidradenitis suppurativa  Manuel Ángel Rodríguez-Prieto, MD, Luis Miguel Valladares-Narganes,
Roser Coll-Fernández, MD, Ramon Coll, MD, PhD, Teresa Pascual, MD, J
Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 
Prognostic Factors and Analysis of Microsatellite Instability in Resected Pulmonary Metastases From Colorectal Carcinoma  Giulio Melloni, MD, Claudio.
Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.
Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience  Maria Teresa Congedo, MD, Alfredo Cesario,
Volume 55, Issue 6, Pages (June 2009)
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer  Francesco Sclafani,
Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.
A Mitral Heart Valve Prosthesis Hidden Under Perivalvular Pannus
Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small.
Reduced oxygen tension improves embryo quality but not clinical pregnancy rates: a randomized clinical study into ovum donation cycles  Maria J. de los.
Initial experience with irreversible electroporation of liver tumours
Immigration and viral hepatitis
Volume 67, Issue 3, Pages (March 2015)
Long-Term Results of a Phase II Trial of Induction Paclitaxel-Carboplatin Followed by Concurrent Radiation Therapy and Weekly Paclitaxel and Consolidation.
J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin 
Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients  Luis Escribano,
Pulmonary Resection for Metastases from Colorectal Cancer
New trials and results in systemic treatment of HCC
Liver transplantation in children
Regional anaesthesia to improve pain outcomes in paediatric surgical patients: a qualitative systematic review of randomized controlled trials  S. Suresh,
Effect of neuraxial anaesthesia on tumour progression in cervical cancer patients treated with brachytherapy: a retrospective cohort study  H Ismail,
High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque  Beatriz Alvarez Garcia, MD, Carmen Ruiz,
The Development of an International Registry
Schema of the exploratory analyses (RAS wild-type population)
How Should End-of-Life Advance Care Planning Discussions Be Implemented According to Patients and Informal Carers? A Qualitative Review of Reviews  Alex.
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.
Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS.
A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.
Physical Activity Behaviors in Individuals with Multiple Sclerosis: Roles of Overall and Specific Symptoms, and Self-Efficacy  Erin M. Snook, MS, Robert.
Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006  Kåre Hornbech, MD, Jesper Ravn, MD, Daniel Andreas.
Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.
R. Parke, S. McGuinness, R. Dixon, A. Jull 
Presentation transcript:

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)  Alfredo Carrato, Albert Abad, Bartomeu Massuti, Cristina Grávalos, Pilar Escudero, Federico Longo-Muñoz, José-Luis Manzano, Auxiliadora Gómez, María José Safont, Javier Gallego, Beatriz García-Paredes, Carles Pericay, Rosario Dueñas, Fernando Rivera, Ferrán Losa, Manuel Valladares-Ayerbes, Encarnación González, Enrique Aranda  European Journal of Cancer  Volume 81, Pages 191-202 (August 2017) DOI: 10.1016/j.ejca.2017.04.024 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Study flow-chart. European Journal of Cancer 2017 81, 191-202DOI: (10.1016/j.ejca.2017.04.024) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Progression-free survival (top) and overall survival (bottom) in the WT-KRAS population and in the WT-RAS population. European Journal of Cancer 2017 81, 191-202DOI: (10.1016/j.ejca.2017.04.024) Copyright © 2017 The Authors Terms and Conditions

Fig. 3 Overall survival according to early tumour shrinkage ≥30% or <30% at week 8 (left) and according to surgical resection of liver metastases (right) in the WT-RAS population. European Journal of Cancer 2017 81, 191-202DOI: (10.1016/j.ejca.2017.04.024) Copyright © 2017 The Authors Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.